SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

MeiraGTx Holdings plc (MGTX) News

Follow MeiraGTx Holdings plc (MGTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol MGTX Asset equity Sector Markets 90 days 7 Last 10.8 Updated Sep 24, 2026, 02:04 PM UTC Open live news feed Open MGTX chart & news
L MeiraGTx Holdings Initiated at Neutral by Goldman Sachs Ratings actions from Benzinga NEWS | Sep 24, 2026, 02:04 PM UTC L MeiraGTx appoints Alan M. Sebulsky to its Board as Class I director MeiraGTx appointed Alan M. Sebulsky to its Board as a Class I director, effective September 23, 2026, and named him to the Science and Technology Committee.Original SEC Filing: MeiraGTx Holdings plc [ MGTX ] - 8-K - Sep. REGULATION | Sep 23, 2026, 12:24 PM UTC L MeiraGTx Holdings plc (MGTX) Appoints Alan M. Sebulsky to Board MeiraGTx Holdings plc appointed Alan M. Sebulsky, a veteran healthcare portfolio manager and analyst, to its Board of Directors.Material DetailsContext by AI AnalystThis is an early-stage governance move supporting Meira NEWS | Sep 23, 2026, 12:01 PM UTC L MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc NASDAQ:MGTX, a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Boa NEWS | Sep 23, 2026, 12:01 PM UTC L MGTX - MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors MGTX - MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors NEWS | Sep 23, 2026, 12:00 PM UTC L MGTX: Graviton BioScience announces Ph1b positive results publication Graviton BioScience said Beijing Tide Pharmaceutical published positive Ph1b trial results for GV101 (TDI01) in chronic graft versus host disease. EQUITY | Aug 26, 2026, 02:50 PM UTC H MeiraGTx reports Q2 2026 financial and operational results MeiraGTx (MGTX) reports its second quarter 2026 financial and operational results, with no additional figures included in the feed. EQUITY | Aug 13, 2026, 12:01 PM UTC